Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVLITE vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Emergency contraception,Contraception (as part of combination oral contraceptives or intrauterine system),Off-label: menstrual disorders, endometriosis
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
400 mg orally once daily with food.
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Hepatic via CYP3A4; reduced to inactive metabolites; excreted in urine and feces.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Levonorgestrel: ~99% bound to sex hormone-binding globulin (SHBG) and albumin; Ethinyl estradiol: ~98% bound to albumin
98% bound to albumin
Levonorgestrel: 1.8 L/kg; Ethinyl estradiol: 2.5 L/kg; clinical meaning: extensive tissue distribution
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: ~100% for both levonorgestrel and ethinyl estradiol (high bioavailability due to minimal first-pass metabolism)
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in severe hepatic disease (Child-Pugh Class C). For mild to moderate impairment (Child-Pugh A/B), use with caution and monitor liver function.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use in postmenarchal pediatric patients; safety and efficacy not established in prepubertal children.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women; no specific geriatric dosing studies available.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use combination hormonal contraceptives.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders,Hepatic disease,Hypertension,Diabetes,Gallbladder disease,Depression,Ectopic pregnancy risk (emergency contraception),Reduced efficacy with CYP3A4 inducers
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Severe hepatic disease,Known or suspected breast cancer,History of thromboembolic disorders,Hypersensitivity to levonorgestrel
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No known significant food interactions. Grapefruit and grapefruit juice do not interact with ethinyl estradiol or levonorgestrel. However, a high-fat meal may increase absorption of some oral contraceptives; consistency in taking with or without food is recommended.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defects from first-trimester exposure. Second and third trimester exposure may be associated with genitourinary abnormalities and masculinization of female fetuses.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in breast milk in small amounts. Ethinyl estradiol concentration in milk ~0.02-0.1 ng/m L; levonorgestrel M/P ratio ~0.35-1.0. No adverse effects reported at typical doses. May reduce milk production; use caution in lactating women, especially with high doses.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dose adjustment applicable as use is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, decreased binding protein) are irrelevant due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
LEVLITE is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Use with caution in women with migraines with aura due to increased stroke risk. Smoking increases cardiovascular risk, especially in women over 35. Monitor blood pressure at baseline and periodically. Consider alternative contraception in women with uncontrolled hypertension or history of venous thromboembolism.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time each day.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Do not smoke while taking this medication, as it increases the risk of blood clots and heart problems.,Use barrier contraception if you also take certain antibiotics or anticonvulsants.,Common side effects include nausea, headache, and breast tenderness, which often improve after a few months.,Seek immediate medical help for symptoms of a blood clot: leg pain/swelling, sudden chest pain, or trouble breathing.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVLITE vs ADQUEY, answered by our medical review team.
LEVLITE is a Oral Contraceptive that works by Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVLITE and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVLITE is: One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVLITE and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVLITE is classified as Category C. FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defec. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.